NBRVF
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q2 | -3.73 | $3M | $511,000 |
| 2023 Q1 | -2.72 | $8M | -$6M |
| 2022 Q4 | -7.32 | $10M | -$2M |
| 2022 Q3 | -4.21 | $9M | -$6M |
| 2022 Q2 | -4.38 | $9M | -$13M |
| 2022 Q1 | -5.03 | $8M | -$16M |
| 2021 Q4 | -5.89 | $9M | -$6M |
| 2021 Q3 | -5.27 | $8M | -$13M |